J&J’s Problems, Pfizer’s Options And Switch Outlook Top “The Tan Sheet” Topics In 2011
This article was originally published in The Tan Sheet
Readers of “The Tan Sheet” in 2011 showed the most interest in stories about Johnson & Johnson’s OTC quality issues, Pfizer’s consumer business maneuvers and Rx-to-OTC switch outlooks. Other hot topics included omega-3 drug development, supplement GMP strategies and state pseudoephedrine laws.
You may also be interested in...
Capsugel CEO Driesen Plots Post-Pfizer Course
Guido Driesen, president and CEO of Capsugel, says the oral dosage technology firm is having a record year after being divested by Pfizer. In an interview, he discusses the firm’s applications for OTC drugs and nutritionals, as well as Capsugel’s international expansion.
Pronova Hopes Rx Omega-3 Success Translates To Supplements
Pronova BioPharma ASA has the capabilities necessary to become “a major player in the new supplement market,” CEO Morten Jurs said. The Norwegian firm likely will spend $10 million to adjust its plant to manufacture consumer products and plans to enter the supplement market in the second half of 2012.